AGL agilon health (AGL) Insider Trading, Ownership & Congress Trades
Healthcare Services · Services-misc health & allied services, nec · CIK 0001831097
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
132
13F, latest reported quarter
agilon health insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for agilon health, inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 53 earlier Form 4 trades (code P or S) here by this insider (53 sales), the last on Sep 13, 2023.
- The trade is 36.6% of the 1,367,674 shares held after it.
- No other insider bought within 30 days.
- 132 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Markets Officer Shaker Benjamin bought about $300.0K of AGL on Mar 2, 2026, the largest insider purchase at the company since 2023; 132 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (1 buy, 4 sales), the last on Dec 5, 2024.
- The trade is 22.1% of the 365,857 shares held after it.
- No other insider bought within 30 days.
- 132 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Wulf John William bought about $51.0K of AGL on Nov 12, 2025; 132 funds added in the latest 13F quarter.170 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
132 funds bought in last quarter
more than 50% of Healthcare Services
Revenue
-2.1% year over year
below 81% of Healthcare Services
Margin
-6.6% net margin
below 62% of Healthcare Services
Buybacks
no share repurchases reported
Short interest
9.2% of the float short (float per yahoo 2026-10-26) · 3.8 days to cover · settled 2026-09-30
more than 71% of Healthcare Services
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch AGL
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+267.7%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns AGL: institutional holders (13F)
13F holdings, latest reported quarter
4,000,000 sh
$428.7M
2,011,196 sh
$215.6M
1,485,066 sh
$159.2M
1,146,520 sh
$122.9M
692,541 sh
$74.2M
Congress trades in AGL
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
AGL planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
AGL mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Inception Portfolio
$25.7M position · as of 2026-06-30
9.1%
EQ/Morgan Stanley Small Cap Growth Portfolio
$20.2M position · as of 2026-06-30
4.2%
Morgan Stanley Insight Fund
$29.4M position · as of 2026-06-30
2.4%
FULLERTHALER BEHAVIORAL MICRO-CAP EQUITY FUND
$686.0K position · as of 2026-06-30
2.3%
Discovery Portfolio
$4.1M position · as of 2026-06-30
2.1%
Discovery Portfolio
$17.1M position · as of 2026-06-30
2.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 132 funds added last quarter. Each figure is a federal filing, dated the day it went public.
AGL financials
Revenue growth
-2.1%
XBRL, annual
Net margin
-6.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$5.9B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM AGL
| FY Dec 2025 | $5.9B |
| FY Dec 2024 | $6.1B |
| FY Dec 2023 | $4.3B |
| FY Dec 2022 | $2.7B |
| FY Dec 2021 | $1.8B |
| Jun 2026 | $1.5B |
| Mar 2026 | $1.4B |
| Dec 2025 | $1.6B |
| Sep 2025 | $1.4B |
| Jun 2025 | $1.4B |
| Mar 2025 | $1.5B |
| Dec 2024 | $1.5B |
| Sep 2024 | $1.5B |
At each fiscal year end
Single quarter
Net margin, TTM
-3.9%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM AGL
| FY Dec 2025 | -6.6% |
| FY Dec 2024 | -4.3% |
| FY Dec 2023 | -6.1% |
| FY Dec 2022 | -3.9% |
| FY Dec 2021 | -22.2% |
| Jun 2026 | +1.2% |
| Mar 2026 | +3.4% |
| Dec 2025 | -12.0% |
| Sep 2025 | -7.7% |
| Jun 2025 | -7.5% |
| Mar 2025 | +0.8% |
| Dec 2024 | -6.9% |
| Sep 2024 | -8.1% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$85.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM AGL
| FY Dec 2025 | -$119.0M |
| FY Dec 2024 | -$71.0M |
| FY Dec 2023 | -$172.0M |
| FY Dec 2022 | -$146.2M |
| FY Dec 2021 | -$154.7M |
| Jun 2026 | -$60.7M |
| Mar 2026 | $20.6M |
| Dec 2025 | -$23.5M |
| Sep 2025 | -$21.3M |
| Jun 2025 | -$38.3M |
| Mar 2025 | -$35.8M |
| Dec 2024 | $13.2M |
| Sep 2024 | -$11.2M |
At each fiscal year end
Single quarter
Debt to equity
0.13x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity AGL
| FY Dec 2025 | 0.28x |
| FY Dec 2024 | 0.07x |
| FY Dec 2023 | 0.06x |
| FY Dec 2022 | 0.04x |
| FY Dec 2021 | 0.04x |
| Jun 2026 | 0.13x |
| Mar 2026 | 0.17x |
| Dec 2025 | 0.28x |
| Sep 2025 | 0.11x |
| Jun 2025 | 0.09x |
| Mar 2025 | 0.07x |
| Dec 2024 | 0.07x |
| Sep 2024 | 0.08x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-2.39x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt AGL
| FY Dec 2025 | -3.02x |
| FY Dec 2024 | -1.66x |
| FY Dec 2023 | -4.05x |
| FY Dec 2022 | -3.01x |
| FY Dec 2021 | -3.06x |
| Jun 2026 | -2.39x |
| Mar 2026 | -1.67x |
| Dec 2025 | -3.02x |
| Sep 2025 | -1.97x |
| Jun 2025 | -1.67x |
| Mar 2025 | -1.20x |
| Dec 2024 | -1.66x |
| Sep 2024 | -3.10x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-73.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity AGL
| FY Dec 2025 | -131.0% |
| FY Dec 2024 | -45.9% |
| FY Dec 2023 | -30.8% |
| FY Dec 2022 | -10.0% |
| FY Dec 2021 | -100.7% |
| Jun 2026 | -73.0% |
| Mar 2026 | -104.0% |
| Dec 2025 | -131.0% |
| Sep 2025 | -70.0% |
| Jun 2025 | -58.2% |
| Mar 2025 | -40.7% |
| Dec 2024 | -45.9% |
| Sep 2024 | -53.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-14.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets AGL
| FY Dec 2025 | -26.0% |
| FY Dec 2024 | -15.0% |
| FY Dec 2023 | -15.3% |
| FY Dec 2022 | -6.5% |
| FY Dec 2021 | -40.0% |
| Jun 2026 | -14.1% |
| Mar 2026 | -20.6% |
| Dec 2025 | -26.0% |
| Sep 2025 | -16.7% |
| Jun 2025 | -16.3% |
| Mar 2025 | -11.4% |
| Dec 2024 | -15.0% |
| Sep 2024 | -17.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital AGL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-83.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed AGL
| FY Dec 2025 | -119.3% |
| FY Dec 2024 | -43.4% |
| FY Dec 2023 | -24.1% |
| FY Dec 2022 | -8.8% |
| FY Dec 2021 | -52.8% |
| Jun 2026 | -83.3% |
| Mar 2026 | -110.6% |
| Dec 2025 | -119.3% |
| Sep 2025 | -72.7% |
| Jun 2025 | -61.3% |
| Mar 2025 | -45.6% |
| Dec 2024 | -43.4% |
| Sep 2024 | -42.0% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
P/E, trailing AGL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$1.4B
market value at close 2026-10-27 on 2026-07-30 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value AGL
| FY Dec 2025 | $7.0B |
| FY Dec 2024 | $19.4B |
| FY Dec 2023 | $127.3B |
| FY Dec 2022 | $165.8B |
| FY Dec 2021 | $264.7B |
| Jun 2026 | $1.7B |
| Mar 2026 | $3.2B |
| Dec 2025 | $7.0B |
| Sep 2025 | $10.5B |
| Jun 2025 | $23.7B |
| Mar 2025 | $44.5B |
| Dec 2024 | $19.4B |
| Sep 2024 | $40.3B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-5.6%
TTM free cash flow over market value at close 2026-10-27
FCF yield AGL
| FY Dec 2025 | -1.7% |
| FY Dec 2024 | -0.4% |
| FY Dec 2023 | -0.1% |
| FY Dec 2022 | -0.1% |
| FY Dec 2021 | -0.1% |
| Jun 2026 | -4.8% |
| Mar 2026 | -1.9% |
| Dec 2025 | -1.7% |
| Sep 2025 | -0.8% |
| Jun 2025 | -0.3% |
| Mar 2025 | -0.1% |
| Dec 2024 | -0.4% |
| Sep 2024 | -0.4% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
PEG, trailing AGL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $5.9B | $6.1B | $4.3B | $2.7B |
| Operating income | -$463.2M | -$292.1M | -$232.1M | -$105.4M |
| Net income | -$391.3M | -$260.2M | -$262.6M | -$106.6M |
| Operating cash flow | -$105.8M | -$57.8M | -$156.2M | -$130.8M |
| Cash | $173.7M | $188.2M | $107.6M | $465.3M |
| Long-term debt | $15.8M | $34.9M | $32.3M | $38.5M |
| Buybacks | n/a | n/a | $200.0M | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
AGL Stock Sonar score 5/7 axes
Find similar shapesCompareAGL ranks highest on institutional and government (58th percentile) and financial health (41st), and lowest on growth (19th), among Healthcare Services peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
